1[5]Lebwohl D, Canetta R.Clinical development of platinum complexes in cancer therapy: an historical perspective and an update [J]. Eur J Cancer,1998,34(10):1 522.
2[9]Uchida N, Takeda Y, Kasai H, et al. Antitumor efficacy of nedaplatin, a novel platinum complex,with cyclophosphamide in murine and human tumor model[J].Anticancer Res, 1998, 18(5A):3 375.
3[10]Kawanishi K, Miyagi Y, Yamamoto J, et al. Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters[J]. Cancer Chemother Pharmacol,2001,47(4):303.
4[11]Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin,tetraplatin, cisplatin and carboplatin: sepctrum of activity in drug-resistant cell lines and in the cell of the national cancer institutes anticancer drug screen panel[J]. Biochem Pharmacol, 1996,52(12): 1 855.
5[13]Ferrante F, Winograd B, Canetta R.Promising new developments in cancer chemotherapy[J]. Cancer Chemother Pharmacol, 1999,43(suppl):61.
6[14]Mckeage M J, Kelland L R, Boxall FE, et al. Schedule dependency of orally administered Bisacetatoamminedichioro-cyclohexyl amineplatinum (Ⅳ)(JM216)in vivo[J]. Cancer Res, 1994,54:4 118.
7[15]Lloyd R Kelland. The development of orally active platinum drugs[C].In:Bemhard L. Chemistry and Biochemistry of a Leading Anticancer Drug .Zuri ch:Verl. Helvetica Chimica Acta ,Weinheim: Wiley VCH,1999:497 ～ 521.
8[16]Desoize B,Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment [J]. Crit Rev Oncol Hematol, 2002, 42(3):317.
9[17]Jakupec MA, Galanski M, Keppler BK.Tumour inhibiting platinum complexes-state of the art and future perspectives [J]. Rev Physiol Biochem Pharmacol,2003,146 : 1.
10[18]Levi F, Giacchetti S, Adam R, et al. Chronomodulation of chemotherapy against metastatic colorectal cancer[J]. Eur J Cancer, 1995, 31A(7/8):1 264.
